Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 223

Sort by

Sort Order Select

Journal Articles

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Jan-Niklas Eckardt, Marius Bill, Konstanze Döhner, Christian Rausch, Klaus H Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. H. Brummendorf, Utz Krug, Bernhard Wörmann, Hermann Einsele, Wolfgang Hiddemann, Dennis Görlich, Maria Cristina Sauerland, Björn Steffen, Andreas Neubauer, Andreas Burchert, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas R Thol, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Mueller-Tidow, Barbora Weinbergerova, Jiri Mayer, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Arnold Ganser, Hartmut Döhner, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood (2024) 144 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2024-201945

Published: 2024

Journal Articles

Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy

Jan-Niklas Eckardt, Ishan Srivastava, Zizhe Wang, Susann Winter, Tim Schmittmann, Sebastian Riechert, Miriam Eva Helena Gediga, Anas Shekh Sulaiman, Martin M. K. Schneider, Freya Schulze, Christian Thiede, Katja Sockel, Frank P. Kroschinsky, Christoph Röllig, Martin Bornhäuser, Karsten Wendt, Jan Moritz Middeke

Blood (2024) 144 (Supplement 1): 1057.

https://doi.org/10.1182/blood-2024-198486

Published: 2024

Journal Articles

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Blood (2024) 144 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2024-194413

Published: 2024

Journal Articles

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

Blood (2024) 144 (Supplement 1): 218.

https://doi.org/10.1182/blood-2024-201058

Published: 2024

Journal Articles

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2024-198861

Published: 2024

Journal Articles

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Maximilian Alexander Rohnert, Jonas Schadt, Michael Kramer, Christoph Röllig, Johannes Schetelig, Friedrich Stölzel, Désirée Kunadt, Jan Moritz Middeke, Lars Thielecke, Friedemann Uschner, Ingmar Glauche, Christian Thiede, Martin Bornhaeuser, Uta Oelschlaegel, Malte von Bonin, Uwe Platzbecker, Claudia D Baldus, Hubert Serve, Carsten Mueller-Tidow

Blood (2024) 144 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2024-194874

Published: 2024

Journal Articles

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Blood (2024) 144 (Supplement 1): 1527.1.

https://doi.org/10.1182/blood-2024-198164

Published: 2024

Journal Articles

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Sarka Pavlova, Jitka Malcikova, Lenka Radova, Silvia Bonfiglio, Jack B. Cowland, Christian Brieghel, Mette Klarskov Andersen, Maria Karypidou, Bella V Biderman, Michael Doubek, Gregory Lazarian, Inmaculada Rapado, Matthijs Vynck, Naomi Porret, Martin Andres, Dina Rosenberg, Dvora Sahar, Carolina Martinez-Laperche, Ismael Buño Borde, Andrew Hindley, Julio Bravo Sánchez, José García-Marco, Alicia Serrano, Blanca Ferrer Lores, Concepción Fernández-Rodriguez, Beatriz Bellosillo, Stephan Stilgenbauer, Eugen Tausch, Hero Nikdin, Fiona Quinn, Emer Atkinson, Lisette Van De Corput, Cafer Yildiz, Cristina Bilbao, Yanira Florido, Christian Thiede, Caroline Schuster, Anastazja Stoj, Sylwia Czekalska, Anastasia Chatzidimitriou, Stamatia Laidou, Audrey Bidet, Charles Dussiau, Friedel Nollet, Giovanna Piras, Tereza Borosova, Terezia Kurucova, Maria Monne, Svetlana Smirnova, Evgeny Nikitin, Ivan Sloma, Marie-Helene Delfau, Laetitia Largeaud, Loic Ysebaert, Peter J. M. Valk, Amy Christian, Renata Walewska, Marta Sebastião, Maria Gomes da Silva, Piero Galieni, Mario Angelini, Davide Rossi, Valeria Spina, Sónia Matos, Vânia Martins, David Donaldson, Tomasz Stoklosa, Monika Pepek, Panagiotis Baliakas, Rafa Andreu, Irene Luna, Tiina Kahre, Ülle Murumets, Sophie Laird, Daniel Ward, Miguel Alcoceba, Ana Balanzategui, Lydia Scarfo, Francesca Gandini, Ettore Zapparoli, Adoracion Blanco, Pau Abrisqueta Costa, Ana E. Rodriguez, Maria Rocio Benito Sanchez, Frédéric Davi, Clothilde Bravetti, Paula Gameiro, Joaquin Martinez-Lopez, Barbara Tazon, Fanny Baran-Marszak, Zadie Davies, Mark Caterwood, Andrey B Sudarikov, Richard Rosenquist, Carsten Utoft Niemann, Kostas Stamatopoulos, Paolo Ghia, Sarka Pospisilova

Blood (2023) 142 (Supplement 1): 200.

https://doi.org/10.1182/blood-2023-173235

Published: 2023

Journal Articles

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Blood (2023) 142 (Supplement 1): 721.

https://doi.org/10.1182/blood-2023-186160

Published: 2023

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 2236.

https://doi.org/10.1182/blood-2023-187273

Published: 2023

Journal Articles

Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence

Jan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, Sebastian Stasik, Uwe Platzbecker, Carsten Müller-Tidow, Hubert Serve, Claudia D Baldus, Christoph Schliemann, Kerstin Schäfer-Eckart, Maher Hanoun, Martin Kaufmann, Andreas Burchert, Christian Thiede, Johannes Schetelig, Martin Bornhäuser, Markus Wolfien, Jan Moritz Middeke

Blood (2023) 142 (Supplement 1): 2268.

https://doi.org/10.1182/blood-2023-179817

Published: 2023

Journal Articles

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2023-174059

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Blood (2023) 141 (15): 1846–1857.

https://doi.org/10.1182/blood.2022018108

Published: 2023

Includes: Supplemental data

Journal Articles

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Blood (2022) 140 (Supplement 1): 739–742.

https://doi.org/10.1182/blood-2022-167138

Published: 2022

Journal Articles

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Blood (2022) 140 (Supplement 1): 523–525.

https://doi.org/10.1182/blood-2022-157126

Published: 2022

Journal Articles

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Blood (2022) 140 (Supplement 1): 6293–6294.

https://doi.org/10.1182/blood-2022-159212

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

Marie Schneider, Clara Rolfs, Matthias Trumpp, Susann Winter, Luise Fischer, Mandy Richter, Victoria Menger, Kolja Nenoff, Nora Grieb, Anne Sophie Kubasch, Klaus H. Metzeler, Katja Sockel, Christian Thiede, Lorenz C Hofbauer, Andreas Roth, Andreas Bruederle, Janghee Woo, Michael Cross, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 4011–4012.

https://doi.org/10.1182/blood-2022-163246

Published: 2022

NARROW

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only